Document is current
Any future updates will be listed below
-
Authors
Crowder, Sylvia L.
Welniak, Taylor L.
Hoogland, Aasha I.
Small, Brent J.
Rodriguez, Yvelise
Carpenter, Kristen M.
Fischer, Stacy M.
Li, Daneng
Kinney, Anita Y.
Rotroff, Daniel
Mariam, Arshiya
Brownstein, Naomi
Reich, Richard R.
Hembree, Tim
Playdon, Mary C.
Arthur, Anna E.
Vieytes, Christian AMaino
Li, Zonggui
Extermann, Martine
Kim, Richard
Berry, Donna L.
Jim, Heather S. L.
- License Information
-
More Information
Article History
Received: 29 June 2022
Accepted: 17 November 2022
First Online: 22 December 2022
Declarations
:
: The study was IRB approved (Identifier: 20180593) and conducted at five US sites: (1) City of Hope, (2) Moffitt Cancer Center, (3) Ohio State University, (4) Rutgers University, and (5) University of Colorado Denver.
: Informed consent was obtained from all individual participants included in the study.
: Dr. Jim is a consultant for Janssen Scientific Affairs and Merck. She has grant funding from Kite Pharma. Dr. Li reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Bayer Healthcare, Coherus BioSciences, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals, Merck, MiNA Therapeutics, QED Therapeutics, Servier, Sun Pharma, Taiho Pharmaceutical, and TerSera Therapeutics. Dr. Brownstein served as an ad-hoc grant reviewer in 2020 for the American Cancer Society, for which she received sponsored travel during the review meeting and a stipend of $300. She also received $500 from the Statistical Consulting Section of the American Statistical Association (ASA) for Best Paper Award at the 2019 Joint Statistical Meetings, a Michael Kutner/ASA Junior Faculty Travel Award of US $946.60 to attend the 2018 Summer Research Conference of the Southern Regional Council on Statistics, and travel support of US $708.51 plus a registration waiver from the ASA to attend and chair a session for the 2017 Symposium on Statistical Inference. Dr. Extermann is a consultant for Aileron and Alnylam, and received honoraria from OncLive and the American Porphyria Foundation. Dr. Rotroff has an equity stake in Clarified Precision Medicine, LLC, has received research support from Novo Nordisk, and consulting honoraria from Pharmazaam, LLC. Dr. Rotroff owns intellectual property related to the treatment of type 2 diabetes, chronic liver disease, liver, and blood cancers.
